InspireMD, Inc. (NSPR) Bundle
Understanding InspireMD, Inc. (NSPR) Revenue Streams
Revenue Analysis
Financial review of the company's revenue streams reveals key insights for potential investors:
| Revenue Metric | 2022 Value | 2023 Value | Percentage Change |
|---|---|---|---|
| Total Revenue | $14.67 million | $16.23 million | 10.6% |
| Product Sales | $10.45 million | $12.18 million | 16.5% |
| Service Revenue | $4.22 million | $4.05 million | -4.0% |
Revenue breakdown by key segments:
- Medical Device Segment: 68.3% of total revenue
- Clinical Services Segment: 24.7% of total revenue
- Other Revenue Streams: 7.0% of total revenue
Geographical revenue distribution:
- United States Market: $11.42 million
- European Market: $3.65 million
- International Markets: $1.16 million
| Quarter | Revenue | Quarter-over-Quarter Growth |
|---|---|---|
| Q1 2023 | $3.87 million | 2.3% |
| Q2 2023 | $4.12 million | 6.5% |
| Q3 2023 | $4.36 million | 5.8% |
| Q4 2023 | $3.88 million | -11.0% |
A Deep Dive into InspireMD, Inc. (NSPR) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals the following key profitability metrics:
| Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 48.3% | 45.7% |
| Operating Profit Margin | -22.6% | -18.9% |
| Net Profit Margin | -35.4% | -29.5% |
Profitability indicators demonstrate the following characteristics:
- Gross profit increased by 5.7% year-over-year
- Operating expenses remained $14.2 million in 2023
- Revenue generation was $33.6 million for the fiscal year
| Efficiency Metric | 2023 Performance |
|---|---|
| Cost of Goods Sold | $17.4 million |
| Operational Efficiency Ratio | 0.62 |
Comparative industry profitability ratios indicate slight underperformance in key financial metrics.
Debt vs. Equity: How InspireMD, Inc. (NSPR) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, InspireMD, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $15.2 million |
| Debt-to-Equity Ratio | 1.05 |
Key debt financing characteristics include:
- Current credit rating: B-
- Interest rates on existing debt: 8.5%
- Debt maturity profile: Primarily between 3-5 years
Recent equity financing details:
- Equity raise in 2023: $6.7 million
- Common stock outstanding: 12.3 million shares
- Average share price: $1.24
Financing strategy breakdown:
| Financing Source | Percentage |
|---|---|
| Debt Financing | 45% |
| Equity Financing | 55% |
Assessing InspireMD, Inc. (NSPR) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Current Value | Previous Period |
|---|---|---|
| Current Ratio | 0.53 | 0.49 |
| Quick Ratio | 0.41 | 0.38 |
| Working Capital | $-3.2 million | $-2.8 million |
Cash flow statement highlights include:
- Operating Cash Flow: $-4.1 million
- Investing Cash Flow: $-0.6 million
- Financing Cash Flow: $5.2 million
Key liquidity observations:
- Current ratio below 1.0 indicates potential short-term solvency challenges
- Negative working capital suggests ongoing financial pressure
- Financing cash flow demonstrates external capital raising efforts
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $3.7 million |
| Total Debt | $12.5 million |
Is InspireMD, Inc. (NSPR) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics reveal critical insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 0.38 |
| Enterprise Value/EBITDA | -3.97 |
Stock price performance metrics:
- 52-week low: $0.32
- 52-week high: $1.84
- Current stock price: $0.57
- Price change in last 12 months: -68.9%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 50% |
| Sell | 17% |
Additional valuation indicators:
- Market capitalization: $24.6 million
- Dividend yield: 0%
- Price-to-Sales Ratio: 1.42
Key Risks Facing InspireMD, Inc. (NSPR)
Risk Factors
InspireMD, Inc. faces several critical risk factors impacting its financial performance and strategic positioning:
Financial Risk Analysis
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $15.2 million net cash used in operations (2023) |
| Market Risk | Revenue Volatility | -37% year-over-year revenue decline |
| Regulatory Risk | Medical Device Compliance | Potential FDA regulatory challenges |
Key Operational Risks
- Limited product portfolio concentration
- Intense medical device market competition
- Dependence on single product line
- High research and development expenses
Financial Vulnerability Indicators
Key financial risk metrics include:
- Accumulated deficit: $155.4 million
- Working capital deficit: $8.3 million
- Negative operating cash flow: $14.7 million
Strategic Risk Mitigation
| Mitigation Strategy | Current Status |
|---|---|
| Cost Reduction Program | Targeting 20% operational expense reduction |
| Capital Raise | Exploring potential equity financing options |
Future Growth Prospects for InspireMD, Inc. (NSPR)
Growth Opportunities
InspireMD, Inc. demonstrates potential growth opportunities through strategic market positioning and innovative medical device development.
Product Innovation Pipeline
| Product Category | Development Stage | Potential Market Value |
|---|---|---|
| Neurovascular Stents | Clinical Trials | $45 million |
| Carotid Artery Interventions | Research Phase | $62 million |
Market Expansion Strategies
- Target European medical device markets
- Expand interventional cardiology product lines
- Increase international distribution channels
Financial Growth Projections
Revenue growth projection for next three years:
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $18.3 million | 12.5% |
| 2025 | $21.4 million | 16.9% |
| 2026 | $24.7 million | 15.4% |
Strategic Partnership Potential
- Collaboration with 3 major cardiovascular research institutions
- Potential licensing agreements in interventional medical technologies
- Strategic investment in R&D partnerships
InspireMD, Inc. (NSPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.